Literature DB >> 24744096

Biochemical characterisation of Troponin C mutations causing hypertrophic and dilated cardiomyopathies.

Athanasia Kalyva1, Fragiskos I Parthenakis, Maria E Marketou, Joanna E Kontaraki, Panos E Vardas.   

Abstract

Cardiac muscle contraction occurs through an interaction of the myosin head with the actin filaments, a process which is regulated by the troponin complex together with tropomyosin and is Ca(2+) dependent. Mutations in genes encoding sarcomeric proteins are a common cause of familial hypertrophic and dilated cardiomyopathies. The scope of this review is to gather information from studies regarding the in vitro characterisation of six HCM and six DCM mutations on the cardiac TnC gene and to suggest, if possible, how they may lead to dysfunction. Since TnC is the subunit responsible for Ca(2+) binding, mutations in the TnC could possibly have a strong impact on Ca(2+) binding affinities. Furthermore, the interactions of mutant TnCs with their binding partners could be altered. From the characterisation studies available to date, we can conclude that the HCM mutations on TnC increase significantly the Ca(2+) sensitivity of force development or of ATPase activity, producing large pCa shifts in comparison to WT TnC. In contrast, the DCM mutations on TnC have a tendency to decrease the Ca(2+) sensitivity of force development or of ATPase activity in comparison to WT TnC. Furthermore, the DCM mutants of TnC are not responsive to the TnI phosphorylation signal resulting in filaments that preserve their Ca(2+) sensitivity in contrast to WT filaments that experience a decrease in Ca(2+) sensitivity upon TnI phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24744096     DOI: 10.1007/s10974-014-9382-0

Source DB:  PubMed          Journal:  J Muscle Res Cell Motil        ISSN: 0142-4319            Impact factor:   2.698


  67 in total

1.  First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy.

Authors:  B Hoffmann; H Schmidt-Traub; A Perrot; K J Osterziel; R Gessner
Journal:  Hum Mutat       Date:  2001-06       Impact factor: 4.878

2.  Mapping of a second actin-tropomyosin and a second troponin C binding site within the C terminus of troponin I, and their importance in the Ca2+-dependent regulation of muscle contraction.

Authors:  B Tripet; J E Van Eyk; R S Hodges
Journal:  J Mol Biol       Date:  1997-09-05       Impact factor: 5.469

3.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.

Authors:  Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

4.  A dilated cardiomyopathy troponin C mutation lowers contractile force by reducing strong myosin-actin binding.

Authors:  David Dweck; Daniel P Reynaldo; Jose R Pinto; James D Potter
Journal:  J Biol Chem       Date:  2010-04-06       Impact factor: 5.157

5.  Calcium affinity of regulatory sites in skeletal troponin-C is attenuated by N-cap mutations of helix C.

Authors:  L Leblanc; A Bennet; T Borgford
Journal:  Arch Biochem Biophys       Date:  2000-12-15       Impact factor: 4.013

6.  Familial hypertrophic cardiomyopathy-related cardiac troponin C mutation L29Q affects Ca2+ binding and myofilament contractility.

Authors:  Bo Liang; Franca Chung; Yang Qu; Dmitri Pavlov; Todd E Gillis; Svetlana B Tikunova; Jonathan P Davis; Glen F Tibbits
Journal:  Physiol Genomics       Date:  2008-02-19       Impact factor: 3.107

7.  Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C.

Authors:  Andrew P Landstrom; Michelle S Parvatiyar; Jose R Pinto; Michelle L Marquardt; J Martijn Bos; David J Tester; Steve R Ommen; James D Potter; Michael J Ackerman
Journal:  J Mol Cell Cardiol       Date:  2008-05-11       Impact factor: 5.000

8.  Structural kinetics of cardiac troponin C mutants linked to familial hypertrophic and dilated cardiomyopathy in troponin complexes.

Authors:  Wen-Ji Dong; Jun Xing; Yexin Ouyang; Jianli An; Herbert C Cheung
Journal:  J Biol Chem       Date:  2007-12-05       Impact factor: 5.157

9.  The C terminus of cardiac troponin I stabilizes the Ca2+-activated state of tropomyosin on actin filaments.

Authors:  Agnieszka Galińska; Victoria Hatch; Roger Craig; Anne M Murphy; Jennifer E Van Eyk; C-L Albert Wang; William Lehman; D Brian Foster
Journal:  Circ Res       Date:  2009-12-24       Impact factor: 17.367

10.  Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy.

Authors:  Jenifer G Crilley; Ernest A Boehm; Edward Blair; Bheeshma Rajagopalan; Andrew M Blamire; Peter Styles; William J McKenna; Ingegerd Ostman-Smith; Kieran Clarke; Hugh Watkins
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

View more
  9 in total

1.  Mechanism of Cardiac Troponin C Calcium Sensitivity Modulation by Small Molecules Illuminated by Umbrella Sampling Simulations.

Authors:  Jacob D Bowman; William H Coldren; Steffen Lindert
Journal:  J Chem Inf Model       Date:  2019-05-29       Impact factor: 4.956

2.  Molecular Dynamics and Umbrella Sampling Simulations Elucidate Differences in Troponin C Isoform and Mutant Hydrophobic Patch Exposure.

Authors:  Jacob D Bowman; Steffen Lindert
Journal:  J Phys Chem B       Date:  2018-08-02       Impact factor: 2.991

3.  Enhanced troponin I binding explains the functional changes produced by the hypertrophic cardiomyopathy mutation A8V of cardiac troponin C.

Authors:  Henry G Zot; Javier E Hasbun; Clara A Michell; Maicon Landim-Vieira; Jose R Pinto
Journal:  Arch Biochem Biophys       Date:  2016-03-11       Impact factor: 4.013

Review 4.  Structure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugs.

Authors:  Monica X Li; Peter M Hwang
Journal:  Gene       Date:  2015-07-29       Impact factor: 3.688

5.  A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy.

Authors:  Jennifer Davis; L Craig Davis; Robert N Correll; Catherine A Makarewich; Jennifer A Schwanekamp; Farid Moussavi-Harami; Dan Wang; Allen J York; Haodi Wu; Steven R Houser; Christine E Seidman; Jonathan G Seidman; Michael Regnier; Joseph M Metzger; Joseph C Wu; Jeffery D Molkentin
Journal:  Cell       Date:  2016-04-21       Impact factor: 41.582

6.  Desensitizing mouse cardiac troponin C to calcium converts slow muscle towards a fast muscle phenotype.

Authors:  Svetlana Tikunova; Natalya Belevych; Kelly Doan; Peter J Reiser
Journal:  J Physiol       Date:  2018-08-02       Impact factor: 5.182

7.  Knock-in mice harboring a Ca(2+) desensitizing mutation in cardiac troponin C develop early onset dilated cardiomyopathy.

Authors:  Bradley K McConnell; Sonal Singh; Qiying Fan; Adriana Hernandez; Jesus P Portillo; Peter J Reiser; Svetlana B Tikunova
Journal:  Front Physiol       Date:  2015-08-27       Impact factor: 4.566

Review 8.  Insights and Challenges of Multi-Scale Modeling of Sarcomere Mechanics in cTn and Tm DCM Mutants-Genotype to Cellular Phenotype.

Authors:  Sukriti Dewan; Kimberly J McCabe; Michael Regnier; Andrew D McCulloch
Journal:  Front Physiol       Date:  2017-03-14       Impact factor: 4.566

9.  A deleterious mutation in the ALMS1 gene in a naturally occurring model of hypertrophic cardiomyopathy in the Sphynx cat.

Authors:  Kathryn M Meurs; Brian G Williams; Dylan DeProspero; Steven G Friedenberg; David E Malarkey; J Ashley Ezzell; Bruce W Keene; Darcy B Adin; Teresa C DeFrancesco; Sandra Tou
Journal:  Orphanet J Rare Dis       Date:  2021-02-27       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.